Wednesday, October 29, 2014 3:02:28 PM
IMO this is a significant overstatement and does at least loosely imply that something is in place and ready to be used.
It is also an overstatement at some significant level that even if say - Flucide and/or Ebolacide works well and works well soon - that the development model used and the development platform used would work on "ANY AND ALL viruses"
That is one of my complaints with what Harris reports when he talks about NNVC - and is one of the reasons that over the years here that many have become disenchanted with the timeline that company has taken to get to this relatively advanced testing point.
The ADIF Technology
http://www.nanoviricides.com/adiftechnology.html
Has huge amounts of potential to be adapted to a broad array of viruses. Potential and reality are two quite different things most of the time.
However - for those viruses where a good 3-D model of a cell-binding ligand can be developed (like for example those on Flucide, or potentially on Ebolacide2) - the potential to develop effective antiviral treatments is very high.
So yes - this statement is (to be kind) premature and could easily be considered deceptive.
It is important to note (however) that the statement was not made by NNVC or its insiders - but rather by an interested outsider with a history of being an avid supporter of NNVC.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM